NOW APPROVED!

The Different Cyclosporine

VEVYE (cyclosporine ophthalmic solution)
0.1% is the first and only water-free
cyclosporine dissolved in a semifluorinated
alkane approved to treat both the signs and
symptoms of dry eye disease.1-3

REQUEST SAMPLES

Shifting the paradigm in dry eye treatment with
semifluorinated alkane technology.1

VEVYE (cyclosporine ophthalmic solution) 0.1% utilizes a novel water-free
vehicle (perfluorobutylpentane) based on semifluorinated alkanes. This allows
VEVYE to spread evenly over the ocular surface with longer residual time
and increased penetration of cyclosporine.1,4

The VEVYE Difference

Rapid Onset 5

  • 66% of subjects had 3 or more grades of tCFS (total corneal fluorescein staining) improvement by Day 29*
  • 57% of patients showed at least 3 grades of improvement in tCFS at Day 15*
  • Provided sustained improvement over 12 months

HIGH PATIENT tolerability 5

  • 99.8% of patients experienced no or mild site instillation irritation*
  • In a 52-week extension study (n=202), only 1 patient discontinued treatment due to an ocular adverse event (mild burning/stinging)
  • Blood concentrations of cyclosporine were below the measurable amount

water-free 1

  • Preservative-free
  • No pH or osmolarity

low surface tension 6-7

  • VEVYE's low surface tension improves the lipid layer grading immediately after administration
  • VEVYE has an ocular residence time of up to 8 hours
*In pooled clinical studies
**A phase 3, prospective, multicenter, open-label study
†An open-label, single-arm safety study
INDICATION AND USAGE: VEVYE® (cyclosporine ophthalmic solution) 0.1% is indicated for the treatment of the signs and symptoms of dry eye disease.
IMPORTANT SAFETY INFORMATION
Warnings and Precautions
Potential for Eye Injury and Contamination – To avoid the potential for eye injury and/or contamination, patients should not touch the bottle tip to the eye or other surfaces.
Use with Contact Lenses – VEVYE should not be administered while wearing contact lenses. If contact lenses are worn, they should be removed prior to administration of the solution. Lenses may be reinserted 15 minutes following the administration of VEVYE.
Adverse Reactions
In clinical trials with 738 subjects receiving at least 1 dose of VEVYE, the most common adverse reactions were instillation site reactions (8%) and temporary decreases in visual acuity (3%).
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
For additional information about VEVYE, please see the Full Prescribing Information.
References: 1. Vevye (cyclosporine ophthalmic solution) 0.1% [package insert]. Harrow IP, LLC; 2023. 2. Restasis (cyclosporine ophthalmic emulsion) 0.05% [package insert]. Allergan, LLC; 2023. 3. Cequa (cyclosporine ophthalmic solution) .09% [package insert]. Sun Ophthalmics, LLC; 2023. 4. Agarwal P, Korward J, Krösser S, Rupenthal ID. Preclinical characterization of water-free cyclosporine eye drops - Factors impacting ocular penetration ex vivo and in vivo. Eur J Pharm Biopharm. 2023 Jul;188:100-107. doi: 10.1016/j.ejpb.2023.05.005. Epub 2023 May 11. PMID: 37178940. 5. Data on file. 6. P. Agarwal, D. Khun, S. Kr¨osser, K. Eickhoff, F.S. Wells, G.R. Willmott, et al., Preclinical studies evaluating the effect of semifluorinated alkanes on ocular surface and tear fluid dynamics, Ocul Surf. 17 (2019) 241–249, https://doi.org/ 10.1016/j.jtos.2019.02.010. 7. Agarwal P, Scherer D, Günther B, Rupenthal ID. Semifluorinated alkane based systems for enhanced corneal penetration of poorly soluble drugs. Int J Pharm. 2018 Mar 1;538(1-2):119-129. doi: 10.1016/j.ijpharm.2018.01.019. Epub 2018 Jan 12. PMID: 29339249.

ARE YOU A PATIENT
OR A HEALTHCARE PROFESSIONAL?

ARE YOU A PATIENT
OR A US HEALTHCARE PROFESSIONAL?